Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

Abstract

Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D.

The Role of Resveratrol in Liver Disease: A Comprehensive Review from In Vitro to Clinical Trials

“…Resveratrol was also found beneficial in type 1 diabetic patients. A two-month trial with 500 mg capsules of resveratrol, administered twice a day reported beneficial effects, such as a reduction in HbA1c (glycosylated haemoglobin), FBS (fasting blood sugar), and oxidative stress marker levels [ 179 ]. A recent meta-analysis even highlighted that in type 2 diabetic patients, resveratrol can reduce C-reactive protein (CRP) levels [ 180 ].…”

Update on the Effects of Antioxidants on Diabetic Retinopathy: In Vitro Experiments, Animal Studies and Clinical Trials

“…Between the baseline and the endpoint resveratrol, treatment was associated with a significant decrease in the level of MDA and a significant increase in the level of total antioxidant capacity. There was no change in the serum levels of TNF-alpha and IL-1beta [ 132 ].…”

Patent Review (2017–2020) of the Keap1/Nrf2 Pathway Using PatSeer Pro: Focus on Autoimmune Diseases

“…Specifically, resveratrol has been shown to maintain the integrity of the blood–brain barrier in experimental autoimmune encephalomyelitis in mice [ 80 ], to confer neuroprotection in a mouse model of multiple sclerosis [ 81 ], to prevent type 1 diabetes in nonobese diabetic mice [ 82 ], and to reduce inflammation in a rheumatoid arthritis mouse model [ 83 ]. Clinical studies on the use of resveratrol against autoimmune diseases are also emerging in rheumatoid arthritis [ 84 ] and in type 1 diabetes [ 85 ].…”